The groups spend big on Terns and Arcellx.
ApexOnco Front Page
Recent articles
J&J’s Tecvayli/Darzalex nod was the second under a new priority voucher scheme.
But Perspective sinks again.
Redemption of sorts comes for IO Biotech, but there’s no respite for Summit.
The company will acquire ImCheck for €350m.
Amgen and Zai Lab’s FGFR2b antibody shows no benefit at the two-year mark.
Response rates with INCB161734 in pancreatic cancer look in line with Revolution.
Harmoni-6 succeeds in first-line lung cancer, but the focus is on changes to Harmoni-3.
